Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Aurora Health Care Germantown Health Center — Germantown, Wisconsin
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Essentia Health-Hayward Clinic — Hayward, Wisconsin
- Tamarack Health Hayward Medical Center — Hayward, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton — Appleton, Wisconsin
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield — Brookfield, Wisconsin
- Ascension Calumet Hospital-Chilton — Chilton, Wisconsin
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Wisconsin: - Cancer Center of Western Wisconsin — New Richmond, Wisconsin
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Wisconsin: - Medical College of Wisconsin ( Site 0020) — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Wisconsin: - Medical College Of Wisconsin — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Wisconsin: - William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin
- Clement J. Zablocki VA Medical Center, Milwaukee, WI — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Wisconsin: - William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Wisconsin: - William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06353386
Sites in Wisconsin: - MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0020) — Milwaukee, Wisconsin
Phase 2 Recruiting Industry
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting NIH
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06022822
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called met…
Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT06150417
Sites in Wisconsin: - Carbone Cancer Center University of Wisconsin-Madison — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be use…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT06675357
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 1 Recruiting Industry
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Sponsor: Alessa Therapeutics Inc.
NCT ID: NCT06257693
Sites in Wisconsin: - Aurora Urology — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…
Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Academic/Other
The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main qu…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT07090148
Sites in Wisconsin: - University of Wisconsin - Madison — Madison, Wisconsin
Phase 1 Recruiting Industry
TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation therapy (ADT…
Sponsor: TechnoGenesys, Inc.
NCT ID: NCT06705686
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect — Madison, Wisconsin
Recruiting Academic/Other
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 C…
Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT03151629
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Wisconsin: - Bellin Memorial Hospital — Green Bay, Wisconsin
NA Recruiting Academic/Other
This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with …
Sponsor: Mayo Clinic
NCT ID: NCT06325046
Sites in Wisconsin: - Mayo Clinic Health System-Eau Claire — Eau Claire, Wisconsin
- Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin